Four drugs firms have been fined £3.4 million (US$4.4 million) with a £1 million (US$1.3 million) payment to be made to the National Health Service (NHS) for conspiring to push up prices of an anti-depressant.
The Competition and Markets Authority (CMA) stated King Pharmaceuticals and the pharma arm of Auden Mckenzie colluded to fix quantities and prices for the supply of nortriptyline to a large drugs wholesaler between September 2014 and May 2015.
The competition watchdog has also hit King, Lexon’s UK business, and Alissa Healthcare Research with penalties for illegally sharing commercially-sensitive information to try to keep nortriptyline prices up between 2015 and 2017.
Nortriptyline is prescribed by the NHS and relied on by thousands of patients every month to relieve the symptoms of depression.
NHS spending on the drug peaked at £38 million (US$48.9 million) in 2015. King and Auden Mckenzie have admitted breaking the law and the CMA stated it was holding the new owner of Auden’s nortriptyline business – Accord-UK – responsible, despite it buying the division after the market-sharing ended.
The CMA has fined King £75,573 (US$97,238.69) and Accord-UK £1.9 million (US$2.4 million).
Full Content:Pharma Intelligence
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Orders Google to Open Android App Store Amid Antitrust Pressure
Oct 7, 2024 by
CPI
Federal Judge Greenlights FTC’s Antitrust Lawsuit Against Amazon, Tosses Some State Claims
Oct 7, 2024 by
CPI
Supreme Court Rejects Uber and Lyft’s Appeal in California Gig Worker Suits
Oct 7, 2024 by
CPI
Supreme Court Sidesteps 5-Hour Energy Pricing Case, Allowing Antitrust Claims to Proceed
Oct 7, 2024 by
CPI
Tempur Sealy and Mattress Firm Argue FTC Proceedings Are Unconstitutional in New Suit
Oct 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh